Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Globally, BRUKINSA is approved in more than 70 countries
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval is based on positive data from the Phase 3 ECHELON-3 trial
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Merck has also decided to end the favezelimab clinical development program
For people with relapsed or refractory diffuse large B-cell lymphoma
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
Subscribe To Our Newsletter & Stay Updated
